Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1AS----4件: 53, 96, 215, 271 💬
2Calcium2件: Calcium,
Calcium carbonate		2件: Calcium carbonate ,
Calcium carbonate 💬		--27件: 6, 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 156, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬
3Calcium gluconate2件: Calcium,
Calcium gluconate		1件: Calcium gluconate 💬--3件: 214, 215, 235 💬
4Coenzyme Q101件: Ubidecarenone1件: Ubidecarenone 💬--11件: 2, 5, 6, 8, 10, 18, 46, 57, 113, 214, 215 💬
5Cold Cadioplegia----1件: 215 💬
6DEXMEDETOMIDINE1件: Dexmedetomidine1件: Dexmedetomidine 💬3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬14件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
7Dexmedetomidine Hcl 100 Mcg/mL Inj1件: Dexmedetomidine1件: Dexmedetomidine 💬3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 215 💬
8Dobutamin1件: Dobutamine1件: Dobutamine 💬1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 215 💬
9Dobutamine1件: Dobutamine1件: Dobutamine 💬1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 57, 58, 86, 215 💬
10Eplerenone1件: Eplerenone1件: Eplerenone 💬1件: NR3C2 💬1件: Aldosterone-regulated sodium reabsorption 💬4件: 75, 113, 210, 215 💬
11Fentanyl1件: Fentanyl1件: Fentanyl 💬1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬3件: 46, 70, 215 💬
12Fentanyl (High Dose)1件: Fentanyl1件: Fentanyl 💬1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 215 💬
13Fentanyl (Low Dose)1件: Fentanyl1件: Fentanyl 💬1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 215 💬
14Fentanyl (Low Dose) + Dexmedetomidine2件: Dexmedetomidine,
Fentanyl		2件: Fentanyl ,
Dexmedetomidine 💬		4件: ADRA2A,
ADRA2B,
ADRA2C,
OPRM1 💬		4件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 215 💬
15Fluorescite----1件: 215 💬
16HTK cardioplegia----1件: 215 💬
17KETAMINE1件: Ketamine1件: Ketamine 💬5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬6件: 6, 13, 70, 113, 156, 215 💬
18Losartan1件: Losartan1件: Losartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
19LOSARTAN POTASSIUM2件: Losartan,
Potassium		2件: Losartan ,
Potassium 💬		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215 💬
20Potassium1件: Potassium1件: Potassium 💬--13件: 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235 💬
21Recombinant human brain natriuretic peptide (rhBNP)----1件: 215 💬
22Sodium citrate1件: Sodium citrate2件: Sodium citrate hydrate ,
Sodium citrate 💬		--4件: 67, 214, 215, 235 💬
23SULFUR HEXAFLUORIDE1件: Sulfur hexafluoride1件: Sulfur hexafluoride 💬--2件: 96, 215 💬
24Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]1件: Sulfur hexafluoride1件: Sulfur hexafluoride 💬--1件: 215 💬
25Tranexamic acid1件: Tranexamic acid1件: Tranexamic acid 💬1件: PLG 💬4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection 💬7件: 46, 70, 215, 227, 274, 288, 299 💬